Metacrine Inc. (MTCR): Price and Financial Metrics

Metacrine Inc. (MTCR): $0.52

0.02 (+3.85%)

POWR Rating

Component Grades













MTCR Stock Price Chart Interactive Chart >

Price chart for MTCR

MTCR Price/Volume Stats

Current price $0.52 52-week high $4.12
Prev. close $0.50 52-week low $0.35
Day low $0.50 Volume 426,200
Day high $0.55 Avg. volume 1,461,343
50-day MA $0.46 Dividend yield N/A
200-day MA $1.04 Market Cap 22.10M

Metacrine Inc. (MTCR) Company Bio

Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.

MTCR Latest News Stream

Event/Time News Detail
Loading, please wait...

MTCR Latest Social Stream

Loading social stream, please wait...

View Full MTCR Social Stream

Latest MTCR News From Around the Web

Below are the latest news stories about Metacrine Inc that investors may wish to consider to help them evaluate MTCR as an investment opportunity.

Metacrine Announces Executive Leadership Changes

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today announced that Ms. Trisha Millican has resigned her position as chief financial officer. Ms. Millican will remain with the Company until March 31, 2022 to ensure a smooth transition. In addition, Mr. Michael York, currently senior vice president, business development and commercial strategy, h

Yahoo | February 24, 2022

Metacrine (MTCR) Receives a Hold from H.C. Wainwright

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Metacrine (MTCR – Research Report) today. The company's shares closed last Friday at $0.49, close to its 52-week low of $0.44. According to, Arce is a 5-star analyst with an average return of 15.6% and a 41.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals. Metacrine has an analyst consensus of Hold, with a price target consensus of $1.25. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $11.00 and a one-year low of $0.44. Currently, Metacrine has an average volume of 3.5M.

Howard Kim on TipRanks | February 11, 2022

Metacrine To Slash Its Workforce By 50%

Metacrine Inc (NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its shares are mired deep in penny stock territory after it floated its IPO in 2020 at $13/share. While NASH was originally Metacrine's priority, the Company abandoned the program back in October after a toxicology study flagged potential delay. Instead, it pushed their FXR agonist, MET642, into a Phase 2 trial for inflammatory bowel disease. Metacrine announced its reorganiz

Yahoo | February 11, 2022

Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan

U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitisSufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis. Metacrine has received authorization from the U.S. Food and Drug

Yahoo | February 11, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Rise and shine, trader!

William White on InvestorPlace | February 1, 2022

Read More 'MTCR' Stories Here

MTCR Price Returns

1-mo 3.59%
3-mo -9.74%
6-mo -11.88%
1-year -84.57%
3-year N/A
5-year N/A
YTD -22.87%
2021 -91.42%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4819 seconds.